{"disease":{"id":"hand-eczema","name":"hand eczema"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04375410","title":"Consequences of Intensified Handwash and Hand Disinfection Among Children During the COVID19 Pandemic","phase":"","overall_status":"COMPLETED","enrollment_count":6273,"lead_sponsor_name":"Regionshospital Nordjylland","has_results":false},{"nct_id":"NCT04949841","title":"Open-label Multi-site Extension Trial in Subjects Who Completed the DELTA 1 or DELTA 2 Trials","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":801,"lead_sponsor_name":"LEO Pharma","has_results":true},{"nct_id":"NCT05259722","title":"A 24 Week Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand Eczema","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":513,"lead_sponsor_name":"LEO Pharma","has_results":true},{"nct_id":"NCT04871711","title":"Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":487,"lead_sponsor_name":"LEO Pharma","has_results":true},{"nct_id":"NCT04872101","title":"Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (DELTA 2)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":473,"lead_sponsor_name":"LEO Pharma","has_results":true},{"nct_id":"NCT06004050","title":"A Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Delgocitinib Cream in Chinese Adults and Adolescents With Moderate to Severe Chronic Hand Eczema","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":362,"lead_sponsor_name":"LEO Pharma","has_results":false},{"nct_id":"NCT05026554","title":"Characterization of Chronic Hand Eczema","phase":"","overall_status":"RECRUITING","enrollment_count":270,"lead_sponsor_name":"Dr. Robert Bissonnette","has_results":false},{"nct_id":"NCT03683719","title":"Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":258,"lead_sponsor_name":"LEO Pharma","has_results":true},{"nct_id":"NCT05958407","title":"A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":235,"lead_sponsor_name":"LEO Pharma","has_results":false},{"nct_id":"NCT05763914","title":"A 24-week Single-blind Trial of Prevention of Hand Eczema in Cleaners","phase":"NA","overall_status":"COMPLETED","enrollment_count":234,"lead_sponsor_name":"Zealand University Hospital","has_results":false},{"nct_id":"NCT04378569","title":"Safety and Efficacy of ARQ-252 Cream in Subjects With Chronic Hand Eczema","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":230,"lead_sponsor_name":"Arcutis Biotherapeutics, Inc.","has_results":true},{"nct_id":"NCT05906628","title":"Topical Ruxolitinib Evaluation in Chronic Hand Eczema","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":186,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT05355818","title":"Efficacy and Safety of Delgocitinib Cream in Adolescents 12-17 Years of Age With Moderate to Severe Chronic Hand Eczema","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":98,"lead_sponsor_name":"LEO Pharma","has_results":true},{"nct_id":"NCT03861455","title":"Efficacy and Safety of Dupilumab Chronic Hands Eczema Refractory to Highly Potent Topical Corticosteroids","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":94,"lead_sponsor_name":"University Hospital, Toulouse","has_results":false},{"nct_id":"NCT06283550","title":"Efficacy, Safety, and Tolerability of Abrocitinib in Subjects With Moderate to Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":82,"lead_sponsor_name":"Innovaderm Research Inc.","has_results":false},{"nct_id":"NCT03246776","title":"Microbial Colonization and Change of Chronic Keratinized Hand Eczema After Using Halometasone Triclosan","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":80,"lead_sponsor_name":"Beijing Friendship Hospital","has_results":false},{"nct_id":"NCT05682859","title":"Treatment of Chronic Hand Eczema With Oral Roflumilast (HERO)","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Jacob Pontoppidan Thyssen","has_results":false},{"nct_id":"NCT06884163","title":"Immune Signature of Chronic Hand Eczema Unveiled by Spatial Transcriptomics and Single-Cell Proteomics","phase":"NA","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT04525521","title":"Hand Sanitizer Effects on the Skin Barrier","phase":"","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"National Jewish Health","has_results":false},{"nct_id":"NCT05486117","title":"Pharmacokinetics of Delgocitinib 20 mg/g Cream in Subjects With Chronic Hand Eczema","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"LEO Pharma","has_results":false},{"nct_id":"NCT05545215","title":"Prospective Real-World Clinical Investigation on Dexyane Med® in Adults With Chronic Hand Eczema","phase":"","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Pierre Fabre Medicament","has_results":false},{"nct_id":"NCT05219864","title":"Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 1","phase":"PHASE3","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT05233410","title":"Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 2","phase":"PHASE3","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Incyte Corporation","has_results":false}],"total":23},"guidelines":[],"source":"Drug Landscape verified database"}